Status:
COMPLETED
Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Hemophilia A
Eligibility:
All Genders
12+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to see if giving azidothymidine (AZT) to HIV-positive patients with hemophilia is safe and if it is effective in lowering HIV levels and boosting the immune system. HIV i...
Detailed Description
There is a clear risk for development of AIDS in hemophilic patients. AZT administration has been shown to inhibit HIV replication in vitro. Patients taking AZT have experienced fewer opportunistic in...
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
- Have a bleeding disorder such as hemophilia A or B, a lack of factor VIII (a blood clotting factor), or severe von Willebrand's disease.
- Will be available for follow-up for at least a year.
- Are at least 12 years old (consent of parent or guardian required if under 18).
- Are willing to use an effective method of birth control during the study.
Exclusion Criteria
You will not be eligible for this study if you:
- Have a life-threatening opportunistic (AIDS-related) infection or AIDS-related symptoms.
- Have taken certain drugs within 30 days prior to study entry including chemotherapy and interferon.
- Are taking acetaminophen or drugs containing acetaminophen.
- Are pregnant or breast-feeding.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
March 1 1989
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00000705
End Date
March 1 1989
Last Update
October 29 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, United States, 14215
2
Univ of Rochester Medical Center
Rochester, New York, United States, 14642